Welcome to our dedicated page for Revolution Medicines SEC filings (Ticker: RVMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Revolution Medicines, Inc. filings document a late-stage clinical oncology company focused on RAS-addicted cancers and RAS(ON) inhibitors. Its Form 8-K reports include financial results, clinical-program updates for daraxonrasib and other pipeline candidates, regulatory-related disclosures and material events tied to corporate progress.
The company’s SEC record also covers proxy governance, annual meeting matters, executive compensation, registered securities and capital-structure changes. Disclosures identify Nasdaq-listed common stock and warrants, and material-agreement filings describe convertible senior notes due 2033, related indenture terms and other financing arrangements used to support research and development, administrative expenses and potential commercialization activities.
Revolution Medicines director Sushil Patel reported option exercises and share sales in RVMD stock. On June 29, 2026, he exercised stock options to acquire 2,955 shares of common stock at an exercise price of $37.54 per share and sold 5,580 shares in a series of open-market transactions.
The sales were executed at weighted-average prices within ranges from $182.93 to $192.64 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on March 30, 2026. After these transactions, Patel directly held 21,656 common shares, including 1,191 restricted stock units.
RVMD reported a Form 144 notice listing proposed sales of Common Stock through Morgan Stanley Smith Barney LLC. The filing lists an exercise of stock options covering 2,955 shares with a sale date of 06/29/2026 and 2,625 Restricted Stock Units with an original date of 06/15/2024.
Revolution Medicines, Inc. Chief Financial Officer Anders Jack reported a combination of stock sales and an option exercise in company shares. On June 24, 2026, he sold 20,000 shares of common stock in multiple open-market transactions at prices generally around $167–$170 per share, executed under a Rule 10b5-1 trading plan adopted on March 24, 2026. On the same date, he exercised stock options to acquire 20,000 shares of common stock at an exercise price of $18.56 per share. After these transactions, he directly owns 123,269 shares of Revolution Medicines common stock, which includes 51,388 restricted stock units.
Jack Anders reported an intended Rule 144 sale of 20,000 shares of Common Stock. The notice lists an intended sale of 20,000 shares on 06/24/2026 arising from an exercise of stock options with a cash settlement method. The filing also discloses a prior sale of 2,722 shares on 06/16/2026 for $424,956.46.
Revolution Medicines, Inc. reported that director Kim Lorence H. received new equity compensation awards. The director was granted 1,191 shares of Common Stock in the form of restricted stock units at no cash cost, increasing direct holdings to 74,281 shares. In addition, the director received a stock option for 3,127 shares of Common Stock with an exercise price of $162.99 per share, expiring on June 18, 2036. The option vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting after the grant date, as long as the director continues as a service provider under the company’s 2020 Plan.
Revolution Medicines director Alexis Borisy reported equity awards from the company. He received 1,191 shares of Common Stock as a grant, bringing his direct holdings to 2,340,075 shares after the transaction. He was also granted options to purchase 3,127 shares of Common Stock at an exercise price of $162.99 per share, expiring on June 18, 2036.
The 1,191 granted shares are structured as restricted stock units. The option will vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting after the grant date, as long as Borisy continues as a Service Provider under the company’s 2020 Plan.
Revolution Medicines director Elizabeth M. Anderson reported compensation-related equity grants and updated holdings. She received 1,191 shares of common stock as a grant of restricted stock units and a stock option for 3,127 shares at an exercise price of $162.99 per share.
The option covers 3,127 shares of common stock and expires on June 18, 2036. These option shares vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting after the grant date, assuming she continues as a service provider.
After these awards, Anderson directly holds 9,406 shares of common stock, which include the 1,191 restricted stock units. Separately, 26,990 shares of common stock are held indirectly through the David W. Anderson 1996 Irrevocable Trust.
Revolution Medicines director Sandra Horning reported equity compensation awards. She received 1,191 shares of common stock at no cost, bringing her direct holdings to 97,765 shares, which include 6,083 restricted stock units. She was also granted a stock option for 3,127 shares at an exercise price of $162.99 per share, expiring on June 18, 2036.
The option vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting, as long as she continues to serve as a service provider under the company’s 2020 plan.
Revolution Medicines director Frank Clyburn reported receiving equity awards in the form of common stock and stock options. He was granted 1,191 shares of Common Stock, increasing his direct holdings to 10,929 shares, and a separate grant of 3,127 Stock Options (Right to Buy) with a $162.99 exercise price, each option for one share of common stock.
The option grant will vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next annual meeting following the grant date, as long as he remains a Service Provider under the company’s 2020 Plan through that vesting date. The filing also notes that his holdings include 4,080 restricted stock units, which typically convert into shares over time.
Revolution Medicines, Inc. director Sushil Patel reported equity awards consisting of common stock and stock options. He received 1,191 shares of Common Stock, which include 1,191 restricted stock units. Following this award, he directly holds 24,281 common shares.
He also received a stock option covering 3,127 shares of Common Stock at an exercise price of $162.99 per share, expiring on June 18, 2036. The option vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the annual meeting following the grant date, subject to his continued service.